Mr. Adair appointed to the role of CEO in March 2024. John has over 25 years of financial and operational experience in the pharmaceutical and medical device arenas. Prior to re-joining Cetya Therapeutics in 2022, John was CFO of Bolder Surgical and led the M&A team during the successful sale of Bolder Surgical to Hologic, Inc. in December 2021. Mr. Adair will retain his position as CFO in addition to his position as CEO of Cetya.